



## Stereotaxis' Market Leadership Highlighted at Heart Rhythm 2009

May 11, 2009

Remote Magnetic Navigation prominently featured on the HRS 2009 program

ST. LOUIS, May 11 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS) said today that the Heart Rhythm 2009 formal program contains 21 podium and poster presentations in which its Niobe system is either featured or discussed regarding the treatment of complex cardiac arrhythmias. These presentations include new efficacy data on the use of Stereotaxis' partnered magnetic irrigated catheter at centers in Copenhagen and Hamburg.

Xu Chen, MD from Rigshospitalet in Copenhagen will present "Acute and long-term outcomes of remote magnetic navigation for ablation of atrial fibrillation using a magnetic irrigated ablation catheter" at a session beginning at 10:30am on Friday, May 15, in Room 162. At the same session, Erik Weissner of Asklepios Klinik St. Georg in Hamburg will present "Magnetically navigated remote pulmonary vein isolation utilizing the second generation 3.5 mm magnetic irrigated tip catheter."

Also, Tamas Szili-Torok, MD of Erasmus Medical Center in Rotterdam and Jinjin Wu, MD of the German Heart Center in Munich will present at Stereotaxis Booth # 778 their experiences with the Niobe Remote Magnetic Navigation System and the treatment of arrhythmias in children. These booth presentations are separate from their independent conference presentations on the same subjects.

At Stereotaxis' booth, Dr. Szili-Torok will speak at 10:00am on Friday; his presentation is titled, "Magnetic Navigation for the Treatment of Pediatric Complex Congenital Arrhythmias." Dr. Wu will present at 3:00pm on Friday with "Mapping of Atrial Tachycardia: Remote Navigation in Post-Operative Patients with Congenital Heart Disease." These presentations will provide a forum for clinicians to share their pediatric experiences and techniques, and demonstrate the growing interest of pediatric electrophysiologists in adding magnetic navigation to their cardiology services.

Against this backdrop of clinical experience, Stereotaxis' Booth # 778 will showcase the simplicity, safety, and efficacy of the Niobe Remote Magnetic Navigation system, the enhanced productivity and procedural efficiency enabled by Navigant 3.0 with QuikCAS, and the full Odyssey information management solution. This includes the new Odyssey Workstation 3.0 software and the Odyssey Cinema(TM) data management system for remote viewing and recording of live interventional cases. This showcase will provide the most comprehensive interactive demonstration of the full Odyssey solution to date, providing clinicians with an opportunity to experience how Odyssey can enhance their institutions' EP practice:

- At two clinical forums during the conference, participants will be able to view and control the playback of complete EP cases on laptops connected to the Odyssey Cinema server, underscoring the unprecedented opportunities for training and sharing of best practices enabled by this peerless technology.
- An Odyssey Connect network link will enable clinicians to use an Odyssey Workstation in Booth # 778 to remotely control a catheter in a Niobe lab in the company's St. Louis headquarters, 1,200 miles away.
- The Odyssey Workstation will be available with a new, state-of-the-art QuadHD display. Quad HD provides four times the resolution of prior, high-definition displays, providing an incredible level of patient detail.

"With our Odyssey Cinema product, we believe that we are building the first true networked clinical environment that can improve care, enhance training and education, maximize cath-lab efficiency, promote best practices and drive hospital referrals," said Michael P. Kaminski, Stereotaxis' President and Chief Executive Officer. "We are pleased with the progress we've made and will continue our investment in Odyssey sales and marketing to take full advantage of our first mover position in this space.

"We also look forward to highlighting the impressive new clinical results that have been achieved with the Niobe Remote Magnetic Navigation system. Stereotaxis' routine appearance in so many presentations and posters speaks to the widespread adoption of our technology by leading electrophysiologists, both for daily clinical practice and scientific discovery. This year we are seeing an important increase in utilization for applications such as ventricular tachycardia and navigation of the unpredictable anatomy associated with congenital heart disease. Our customers report that magnetic navigation is uniquely suited to these important market segments, highlighting the platform's versatility in every chamber. We are confident that it will continue to transform interventional medicine well into the future."

Heart Rhythm 2009, the Heart Rhythm Society's 30th Annual Scientific Sessions, will be held at the Boston Convention and Exhibition Center, May 13 -- 16, 2009.

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. The Stereotaxis system is designed to enable physicians to complete more

complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe, Canada and elsewhere.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company's products in the marketplace, the effect of global credit and economic conditions on the ability and willingness of customers to purchase our systems, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approval and return of the irrigated catheter to the market, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.

SOURCE Stereotaxis, Inc.

-0- 05/11/2009  
/CONTACT: Jim Stolze, Chief Financial Officer of Stereotaxis, Inc.,  
+1-314-678-6105; or Investors, Doug Sherk or Jenifer Kirtland,  
+1-415-896-6820, or Media, Steve DiMattia, +1-646-201-5445, all of EVC Group,  
Inc., for Stereotaxis, Inc./  
/Web Site: <http://www.stereotaxis.com> /  
(STXS)

CO: Stereotaxis, Inc.; Heart Rhythm 2009; Heart Rhythm Society

ST: Missouri, Massachusetts  
IN: HEA MTC  
SU: TDS

PR  
-- SF14891 --  
6491 05/11/2009 16:04 EDT <http://www.prnewswire.com>